Essential role of the imidazoline moiety in the insulinotropic effect but not the KATP channel-blocking effect of imidazolines; A comparison of the effects of efaroxan and its imidazole analogue, KU14R

Diabetologia

Volumn 48, Issue 12, 2005, Pages 2567-2575

  Bleck, C ^a   Wienbergen, A ^a   Rustenbeck, I ^a  

^a TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

Author keywords

Cytosolic calcium concentration; Imidazolines; Insulin secretion; K ATP channel; Pancreatic islets; Plasma membrane potential

Indexed keywords

CALCIUM; EFAROXAN; GLUCOSE; IMIDAZOLINE DERIVATIVE; KU 14 R; POTASSIUM; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CELL ISOLATION; CELL MEMBRANE DEPOLARIZATION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; ENERGY METABOLISM; HILL REACTION; IC 50; INSULIN LIKE ACTIVITY; INSULIN RELEASE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; STIMULUS SECRETION COUPLING; STRUCTURE ANALYSIS;

ACTION POTENTIALS; ANIMALS; BENZOFURANS; CALCIUM; CELL LINE; CYTOSOL; IMIDAZOLES; IMIDAZOLINES; INSULIN; INSULIN-SECRETING CELLS; MEMBRANE POTENTIALS; MICE; MICE, MUTANT STRAINS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS;

EID: 28444494756     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-0031-4     Document Type: Article

References (38)

1. Morgan NG (1999) Imidazoline receptors: targets for novel antihyperglycemic agents. Exp Opin Invest Drugs 8:575-584
2. Rustenbeck I, Leupolt L, Kowalewski R, Hasselblatt A (1999) Heterogeneous characteristics of imidazoline-induced insulin secretion. Naunyn-Schmiedeberg's Arch Pharmacol 359:235-242
3. Bleck C, Wienbergen A, Rustenbeck I (2004) Glucose-dependence of imidazoline-induced insulin secretion. Diabetes 53:S135-S139
4. Robertson RP, Porte D (1973) Adrenergic modulation of basal insulin secretion in man. Diabetes 22:1-8
5. Efendic S, Cerasi E, Luft R (1975) Effect of phentolamine and preperfusion with glucose on insulin release from the isolated perfused pancreas from fasted and fed rats. Diabetologia 11:407-410
6. Schulz A, Hasselblatt A (1989) An insulin-releasing property of imidazoline derivatives is not limited to compounds that block α-adrenoceptors. Naunyn-Schmiedeberg's Arch Pharmacol 340:321-327
7. 2-adrenoceptor blockade does not enhance glucose-induced insulin release in normal subjects or patients with non insulin-dependent diabetes. J Clin Endocrinol Metab 67:1054-1059
8. Chan SLF, Scarpello KE, Morgan NG (1997) Identification and characterization of non-adrenergic binding sites in insulin-secreting cells with the imidazoline RX821002. Adv Exp Med Biol 426:159-163
9. ATP channels in pancreatic B-cells. Naunyn-Schmiedeberg's Arch Pharmacol 356:410-417
10. Eglen RM, Hudson AL, Kendall DA et al. (1998) Seeing through a glass darkly: casting light on imidazoline 'I' sites. Trends Pharmacol Sci 19:381-390
11. 2-adrenoceptor antagonist efaroxan is mediated by a novel, stereoselective, binding site. Eur J Pharmacol 230:375-378
12. 2 sites. Br J Pharmacol 112:1065-1070
13. + channels in pancreatic β-cells. Br J Pharmacol 107:8-14
14. ATP channels is mediated by Kir6.2. Proc Natl Acad Sci USA 94:11716-11720
15. Monks LK, Cosgrove KE, Dunne M, Ramsden C, Morgan NG, Chan SLF, (1999) Affinity isolation of imidazoline binding proteins from rat brain using 5-amino-efaroxan as a ligand. FEBS Lett 447:61-64
16. + channels. Ann NY Acad Sci 1009:371-377
17. ATP channels and interaction with the exocytotic machinery. Diabetes 45:1610-1618
18. Chan SLF, Palett AL, Clews CA et al. (1998) Characterization of new efaroxan derivatives for use in purification of imidazoline-binding sites. Eur J Pharmacol 355:67-76
19. Morgan NG, Chan SLF (2001) Imidazoline binding sites in the endocrine pancreas: can they fulfil their potential as targets for the development of new insulin secretagogues? Curr Pharm Des 7:1413-1431
20. Ball AJ, Flatt PR, McClenaghan N (2000) Stimulation of insulin secretion in clonal BRIN-BD11 cells by the imidazoline derivatives KU14R and RX801080. Pharmacol Res 42:575-579
21. Mayer G, Taberner PV (2002) Effects of the imidazoline ligands efaroxan and KU14R on blood glucose homeostasis in the mouse. Eur J Pharmacol 454:95-102
22. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ (1981) Improved patch-clamp techniques for high-resolution current recordings from cells and cell-free membrane patches. Pflügers Arch 391:85-100
23. + channels in mouse pancreatic beta-cells. Pflügers Arch 407:493-499
24. +-currents in isolated mouse pancreatic beta-cells. FEBS Lett 261:187-190
25. +-channels from pancreatic B-cells. FEBS Lett 239:241-244
26. + channels. Life Sci 73:429-435
27. ATP channels in insulin-secreting cells. Eur J Pharmacol 204:41-48
28. ATP channels by binding to Kir6.2. Biochem Biophys Res Commun 251:477-481
29. 2+ mobilization from thapsigargin-sensitive stores in mouse pancreatic β-cells. Diabetes 47:211-218
30. Henquin JC (2000) Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49:1751-1760
31. Chan SLF, Morgan NG (1990) Stimulation of insulin secretion by efaroxan may involve interaction with potassium channels. Eur J Pharmacol 176:97-101
32. ATP channel-independent pathway involved in potentiation of insulin secretion by efaroxan. Diabetes 50:340-347
33. Schulz A, Hasselblatt A (1989) Dual action of clonidine on insulin release: suppression, but stimulation when α-adrenoceptors are blocked. Naunyn-Schmiedeberg's Arch Pharmacol 340:712-714
34. Page T, Bailey C (1997) Glucose-lowering effect of BTS 67 582. Br J Pharmacol 122:1464-1468
35. McClenaghan NH, Flatt PR, Bailey C (1998) Insulin releasing action of the novel antidiabetic agent BTS 67 582. Br J Pharmacol 123:400-404
36. ATP channel activity. Diabetes 50:797-802
37. 2+-dependent exocytosis in pancreatic α- and β-cells. Eur J Pharmacol 446:213-221
38. Efendic S, Efanov A, Berggren PO, Zaitsev SV (2002) Two generations of insulinotropic imidazoline compounds. Diabetes 51:S448-S454